Multidisciplinary Association for Psychedelic Studies

Zinger Keypoints: Long-term (over 1 year) follow-up reflects lasting improvements in symptom severity. Data confirms prior Phase 2 studies on MDMA-assisted therapy’s sustained effect on PTSD treatment. New Drug Application (NDA) to be submitted in Q3 2023 would be the last...

The historical non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) has announced the agenda and featured speakers of its Psychedelic Science 2023 conference taking place June 19-25, 2023 in Denver, Colorado, organized by Momentum Events. With an estimated 10,000...

In its capacity as a financial news and media outlet, Benzinga has added six new members to its Psychedelics Advisory Council. The new members include renowned author Amanda Siebert; Revitalist Lifestyle & Wellness (OTCMKTS: RVLWF) CEO Kathryn Walker; Inbodied Life...

Palo Santo, a venture capital fund focused on backing and building emerging psychedelic therapeutics companies, recently announced the closing of its $50 million fund. The oversubscribed fund is positioned to have a transformative impact on the field of mental health by funding a diverse portfolio...

In recent months, the psychedelics space has been ground for increasing collaborations. In some cases it was to advance scientific studies. In others, to offer psychedelic medicine, therapy training and clinical retreats.   This time, a partnership has been set between Sunstone...

Patents are the golden eggs of the booming psychedelic space. In an industry that revolves around substances that are found in nature (such as psilocybin, ibogaine or DMT) or compounds whose patents have already expired (LSD and MDMA), new patents are the primary way in which companies can ...

The non-profit Multidisciplinary Association for Psychedelics Studies (MAPS) and its subsidiary MAPS Public Benefit Corporation finished the enrollment stage for the second Phase 3 clinical trial on MDMA (MAPP2). A year later after publishing the results from its first Phase 3 trial...

The Drug Enforcement Administration (DEA) will face activists at its headquarters in Arlington, Virginia, reported Mary-Elizabeth Gifford and Justin Grant of Lucid News. Protestors intend to block the entrance to the building to call attention to the rights of terminally ill...

Numinus Wellness Inc. (OTCQX: NUMIF), announced that clinical trial MAPPUSX has gotten underway with the enrolling and dosing of the first trial volunteer in Canada. MAPPUSX, which stands for "A multi-site open-label extension study of MDMA-assisted psychotherapy for PTSD”, is...

In the quest to design effective and affordable psychedelic treatments for a range of maladies that include PTSD and depression, one key thought on the minds of company executives and clinicians alike seems to be how to motivate healthcare insurance companies to cover the cost of psychedelic...

The Australian state of Victoria faces a seminal lawsuit that seeks to make MDMA available for severe mental illness. Attempting to secure permission to treat a gravely ill patient using MDMA (universally known as the street drug ecstasy), psychiatrist Dr. Eli Kotler initiated legal...

Wesana Health (CSE: WESA) (OTCQB: WSNAF) and the Multidisciplinary Association for Psychedelic Studies (MAPS) are teaming up to analyze the effectiveness of MDMA-assisted therapy in the treatment of traumatic brain injury (TBI). Wesana Health went public in May with a focus on developing...

This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Psilocybin Alpha. In just a couple of years, psychedelics took the world of investing by storm. What in 2019 was merely a buzzword for investors became a full-fledged industry boasting over 25...

The results from the world’s first Phase 3 clinical study on a psychedelic are in — and they’re significant. The Multidisciplinary Association for Psychedelic Studies released the results from its Phase 3 trial on MDMA for the treatment of post-traumatic stress disorder. ...

In 2020, psychedelics took the world by storm. Over two dozen companies in the sector became publicly listed.  The industry grew closer to federal legalization of the first psychedelic compounds for therapeutic use. With scientific, regulatory and corporate developments becoming...